Yes, the poor $BDX performance is actually surprising at this late stage in development.
Also,the Becton Dickinson CEO realizes their test is very expensive at $20.00 per test. He tried to minimize the expense because it is 50% cheaper than the current PCR tests.
$ABMC should get some traction from this exposure when it is found to be better performing and at less cost.